أعرض في EDS

PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC)

التفاصيل البيبلوغرافية
العنوان:	PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC)
المؤلفون:	Narin Voravud, Jong Seok Lee, Abdul Muthalib, Li Zhang, Chih-Hsin Yang, Joseph Siu-Kie-Au, Keunchil Park, Ashley Cheng, Mohd Ibrahim A. Wahid, Yi-Long Wu
المصدر:	Journal of Thoracic Oncology. 2:S464-S465
بيانات النشر:	Elsevier BV, 2007.
سنة النشر:	2007
مصطلحات موضوعية:	Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, non-small cell lung cancer (NSCLC), medicine.disease, Internal medicine, Interim, Treatment study, medicine, South east, Erlotinib, Open label, Lung cancer, business, medicine.drug
تدمد:	1556-0864
URL الوصول:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3030c26f92acb0aef4d0f84595699047 https://doi.org/10.1097/01.jto.0000283408.85001.f3
حقوق:	OPEN
رقم الأكسشن:	edsair.doi.dedup.....3030c26f92acb0aef4d0f84595699047
قاعدة البيانات:	OpenAIRE

الوصف
تدمد:	15560864